Clinical Trial Update: A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ipatasertib plus paclitaxel in PI3K/AKT/PTEN-altered locally advanced or metastatic triple-negative breast cancer or HR-positive/HER2-n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-03-12